Enliven: Challenges in Cancer Detection and Therapy | Open Access Journals | Open Access Articles

saurabh-saha

Saurabh Saha MD, PhD


Editorial Board Member



"Dr. Saurabh Saha is a physician‐scientist and biotech/pharmaceutical executive. His publications include numerous highly cited papers in the field of cancer genetics, and his work has been featured in The Wall Street Journal and The Economist. Dr. Saha’s published research has tackled: The discovery of the first genetic mutation in metastatic cancer (Science, 2001); the co‐development of the first method to identify human genes unambiguously (Nature Biotechnology, 2002); and the first systematic mutational analysis of a gene family in any human cancer type (Science, 2003) ‐ an approach which spearheaded the subsequent large‐scale sequencing of genes mutated in human cancers by research labs around the world. Dr. Saha currently serves as President of BioMed Valley Discoveries. A translational research and development company, BioMed seeks to improve human health and advance science by discovering new therapeutics and diagnostics for diseases with unmet medical need. While at BioMed, Dr. Saha pioneered the development of multiple novel cancer therapies and radiopharmaceutical diagnostics into human clinical trials. Prior to BioMed, Dr. Saha was Head of the New Indications Discovery Unit at Novartis Pharmaceuticals and Chief Medical Officer of the Developmental and Molecular Pathways division. At Novartis, he used innovative methods to identify and discover drugs for so‐called orphan diseases—taking them from discovery to clinical trials. His work led to the creation of a successful research program for a novel drug target for Third World diarrhea and a subsequent partnership with OneWorld Health and the Gates Foundation. Before joining Novartis, Dr. Saha served as a consultant in the Pharmaceuticals and Medical Products Practice at McKinsey & Company in New York City where his clients included private equity/venture capital firms, investment banks, and large pharmaceutical companies. Dr. Saha received his M.D. and Ph.D. in cancer genetics from The Johns Hopkins School of Medicine under renowned cancer researcher Dr. Bert Vogelstein. Dr. Saha is a graduate of Harvard Business School and Oxford University, studying general management and biophysics respectively. He completed his undergraduate degree in biochemistry at the California Institute of Technology (Caltech), graduating in 2.5 years at the top of his class."